Wuxi Further Pharmaceutical Co., Ltd is an innovation-driven and service-oriented pharmaceutical hi-tech company. Its’ international trading department mainly specializes in exporting a variety of API, pharmaceutical intermediates, food additives and dietary supplements etc.

The company's products cover the treatment fields of the cardiovascular, central nervous, diabetes. The core products API such as Voglibose, Avanafi, Cozotinib, Dietary supplements, e.g Palmitoylethanolamide(PEA), Urolithin A, Spermidine HCL and other products have formed a commercialized R&D, production and sales system of the whole industrial chain.

Further Pharmaceutical possesses reliable production base, located in Yangzhou city, Jiangsu province. Its advanced equipment and exquisite technology can assure the quality of products. The staff numbers are more than 300 and the square of the factory is around 20,000m2, which have achieved large-scale autonomously production. The workshop production system conforms to ISO，GMP regulation and standard administration. Besides, our new factory gradually comes into use in the near future.

Wuxi Further R&D Center has Medicinal Chemistry Platform, Analytical Technology Platform, Impurities Directional Preparation Technology Platform, Innovative Synthesis Technology Platform . And many professional technical staff with Ph.D. and Master degree are enrolled , who have rich experience in chemical and pharmaceutical researches. Therefore, good quality and professional service can be guarantee for the customers. Besides, our company attaches great importance to the protection of customers' intellectual property and trade secrets.

With rigorous quality management and EHS management capabilities, high standard and large-scale production and manufacturing capacity, as well as fine and efficient teamwork, the company has established long-term deep and stable cooperation relationships with well-known domestic and foreign pharmaceutical companies. In the CDMO segmentation industry and the characteristic API segmentation industry, the company has formed a high international brand awareness and competitive advantages.

The company has taken advantage of the pharmaceutical R&D and production capacity, driven by the two wheels of "connotative growth + extensional expansion". While consolidating and strengthening the business of characteristic APIs and Intermediates, relying on continuous R&D innovation and business expansion, the company has firmly deepened the integration strategy of "pharmaceutical intermediates, APIs and preparations", expanded and extended the business of upstream intermediates and downstream preparations to further improve the layout of the industrial chain and fully expand the integration advantage; At the same time, based on its competitive advantages in the field of characteristic APIs and customer network resources, the company continued to deploy CDMO business and is committed to building Further into a domestic first-class, internationally renowned and highly competitive international pharmaceutical science and technology manufacturing enterprise.

Jiangsu Further Pharmaceutical Co., Ltd was established in January 2012 at the exclusive medical-centric national level high-tech industrial park-Taizhou Medical City High-Tech Industrial Park. Main business of Jiangsu Further is the clinical research for drug development, including Phase Ⅰ-Ⅳ trials, clinical pharmacokinetics(PK), bioequivalence(BE) studies. We have highly educated professional team of clinicians, clinical research associates, and medical monitors as well as reliable quality management and control system to ensure the compliance to ICH-GCP and Chinese GCP requirements and the acquisition of high quality clinical research data.

In 2016, we have built another research firm, which is located at Wuxi City, China by beautiful Tai lake Shore and registered in prestigious Wuxi(Huishan) Life Science & Technology Industrial Park. We were found with mission to create the highest quality of global Research & Development, manufacturing and marketing chain for small molecule and biologics innovative and generic drugs as well as pharmaceutical intermediates, APIS, and macromolecule polymers/biomaterials with our own IP and innovative drug delivery/formulation technologies.

In addition, we mainly focus on medical/pharmaceutical information and regulatory consultin, API DMF application, Drug products clinical development and IND/NDA submission, Reference listed drug procurement, medical raw material API and intermediates export.

Our R&D Center at Wuxi has Generic Drugs Bioequivalence Evaluation Platform, Medical Chemistry Platform, Impurities Directional Preparation Technology Platform, Innovative Formulation Platform, Analytical Technology Platform.

Wuxi Further has professional R&D research team. Many technical staff with Ph.D. and Master degree are enrolled , who have rich experience in chemical and pharmaceutical researches. Therefore, good quality and professional service can be guarantee for the customers. Besides, our company attaches great importance to the protection of customers' intellectual property and trade secrets.

R&D Center has four professional platforms, which are Medicinal Chemistry Platform, Analytical Technology Platform, Impurities Directional Preparation Technology Platform and Innovative Synthesis Technology Platform.

In addition, for international business, we have experienced and well-educated foreign trade salesmen. They can offer customers detailed quotation, and give a prompt reply.

Meeting customers' demand and offering good service are our final goal.